1例重症患者抗感染个体化给药策略分析

石晓萍; 吕迁洲; 杨婉花; 方洁

doi:10.3969/j.issn.1006-0111.2017.06.018

1例重症患者抗感染个体化给药策略分析

doi: 10.3969/j.issn.1006-0111.2017.06.018

1.
复旦大学附属中山医院药剂科, 上海 200032
2.
上海交通大学医学院附属瑞金医院药剂科, 上海 200025

The individualized anti-infective treatment strategy for a critically ill patient

1.
Department of Pharmacy, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, China
2.
Department of Pharmacy, Ruijin Hospital Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China

摘要: 目的探讨对于重症感染的患者如何根据其特殊的病理生理状况制订个体化抗感染治疗方案。方法临床药师参与1例急性泛发性发疹性脓疱病继发血流感染和肺部感染患者的抗感染治疗，通过分析其病理生理状况，运用治疗药物监测，协助临床医生制订个体化的给药方案。结果患者初始抗感染治疗方案效果不佳，临床药师根据患者的个体情况和血药浓度监测结果调整给药方案，患者的感染得到控制，病情好转。结论确保重症患者给药剂量达到药动学/药效学目标值是治疗成功的关键。
- 急性泛发性发疹性脓疱病 /
- 药物监测 /
- 万古霉素 /
- 阿米卡星
Abstract: Objective To design individualized anti-infective therapy for a critically ill patient. Methods Based on pathophysiological conditions and therapeutic drug levels,clinical pharmacists assisted physicians to optimize individual anti-infective medication regimens for a patient with acute generalized exanthematous pustulosis secondary to blood stream infection and pulmonary infection. Results The patient responded poorly to initial treatment. After the medication regimen adjustments byclinical pharmacists according to the individual situation and therapeutic drug monitoring results,patient's condition was improved and the infection was under control. Conclusion The key to successful treatment is to ensure the dosage administered to the critically ill patients reach the target value of pharmacokinetics and pharmacodynamics.
- acute generalized exanthematous pustulosis /
- therapeutic drug monitoring /
- vancomycin /
- amikacin

[1]	Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children[J]. Clin Infect Dis, 2011,52(3):e18-e55.
[2]	Truong J, Levkovich BJ, Padiglione AA. Simple approach to improving vancomycin dosing in intensive care:a standardised loading dose results in earlier therapeutic levels[J]. Intern Med J, 2012,42(1):23-29.
[3]	万古霉素临床应用剂量专家组. 万古霉素临床应用剂量中国专家共识[J]. 中华传染病杂志, 2012,30(11):641-646.
[4]	桑德福. 热病:桑德福抗微生物治疗指南[M]. 范洪伟译. 44版.北京:中国协和医科大学出版社, 2014:96-109.
[5]	Martin JH, Norris R, Barras M, et al. Therapeutic monitoring of vancomycin in adult patients:a consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists[J]. Clin Biochem Rev, 2010,31(1):21-24.
[6]	van Hal SJ, Fowler VJ. Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?[J]. Clin Infect Dis, 2013,56(12):1779-1788.
[7]	Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill:challenges and potential solutions[J]. Lancet Infect Dis, 2014,14(6):498-509.
[8]	Rostas SE, Kubiak DW, Calderwood MS. High-dose intravenous vancomycin therapy and the risk of nephrotoxicity[J]. Clin Ther, 2014,36(7):1098-1101.
[9]	Arimura Y, Yano T, Hirano M, et al. Mitochondrial superoxide production contributes to vancomycin-induced renal tubular cell apoptosis[J]. Free Radic Biol Med, 2012,52(9):1865-1873.
[10]	Mulazimoglu L, Drenning SD, Yu VL. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis[J]. Antimicrob Agents Chemother, 1996,40(10):2428-2430.
[11]	Jacqueline C, Caillon J, Le Mabecque V, et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods[J]. J Antimicrob Chemother, 2003,51(4):857-864.
[12]	Singh SR, Bacon AR, Young DC, et al. In vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureus[J]. Antimicrob Agents Chemother, 2009,53(10):4495-4497.
[13]	Chiang FY, Climo M. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus[J]. Antimicrob Agents Chemother, 2003,47(9):3002-3004.
[14]	Beibei L, Yun C, Mengli C, et al. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections:meta-analysis of randomised controlled trials[J]. Int J Antimicrob Agents, 2010,35(1):3-12.
[15]	穆玉, 范春芳, 朱铁梁, 等. 重症患者利奈唑胺所致血小板减少危险因素分析[J]. 中国感染与化疗杂志, 2012,12(1):10-14.
[16]	Kalil AC, Metersky ML, Klompas M, et al. Executive summary:management of adults with hospital-acquired and ventilator-associated pneumonia:2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society[J]. Clin Infect Dis, 2016,63(5):575-582.
[17]	Zelenitsky SA, Harding GK, Sun S, et al. Treatment and outcome of Pseudomonas aeruginosa bacteraemia:an antibiotic pharmacodynamic analysis[J]. J Antimicrob Chemother, 2003,52(4):668-674.
[18]	Kato H, Hagihara M, Hirai J, et al. Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen[J]. Drugs RD, 2017,17(1):177-187.
[19]	Duszynska W, Taccone FS, Hurkacz M, et al. Therapeutic drug monitoring of amikacin in septic patients[J]. Crit Care, 2013,17(4):R165.
[20]	付双双, 唐惠林, 段京莉. 抗感染药物治疗药物监测的Meta分析[J]. 中国新药杂志, 2013,22(15):1840-1848.
[21]	梅清, 喻婷, 朱玉林, 等. 万古霉素单用及联合利福平或磷霉素对耐甲氧西林金黄色葡萄球菌防耐药突变浓度的研究[J]. 中国药理学通报, 2011,27(7):944-947.
[22]	胡文, 邓国泉, 伍婷, 等. 万古霉素单用与联用磷霉素治疗耐甲氧西林金黄色葡萄球菌肺部感染的疗效比较[J]. 实用中西医结合临床, 2012,12(4):6-7.
[23]	中华医学会呼吸病学分会《雾化吸入疗法在呼吸疾病中的应用专家共识》制定专家组. 雾化吸入疗法在呼吸疾病中的应用专家共识[J]. 中华医学杂志, 2016,96(34):2696-2708.

[1]	迟文雅, 袁艳, 李伟林, 吴茼妤, 俞媛. 负载骨髓间充质干细胞/白藜芦醇脂质体的水凝胶支架用于创伤性脑损伤治疗 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202406034
[2]	戴菲菲, 傅翔, 陈琼年, 俞苏纯. 上海某二级医院革兰阴性菌流行特征的回顾性分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202305005
[3]	唐淑慧, 凤美娟, 薛智霞, 鲁桂华. 帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
[4]	桂明珠, 李静, 李志玲. 儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
[5]	王耀振, 徐灿, 吕顺莉, 田泾, 张东炜. 钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
[6]	张晶晶, 索丽娜, 郑兆红. 89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
[7]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
[8]	陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾. 基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 479-486. doi: 10.12206/j.issn.2097-2024.202401073
[9]	徐飞, 陈瑾, 鲁育含, 李志勇. 肠道菌群参与糖尿病肾病的机制研究进展 . 药学实践与服务, 2024, 42(5): 181-184, 197. doi: 10.12206/j.issn.2097-2024.202312023
[10]	丁华敏, 郭羽晨, 秦春霞, 宋志兵, 孙莉莉. 消风止痒颗粒通过降低白三烯水平对小鼠特应性皮炎急性瘙痒的治疗作用研究 . 药学实践与服务, 2024, 42(5): 211-216. doi: 10.12206/j.issn.2097-2024.202306031
[11]	宋泽成, 陈林林, 鲁仁义, 刘梦肖, 王彦. 脓毒症治疗的研究进展 . 药学实践与服务, 2024, 42(11): 457-460, 502. doi: 10.12206/j.issn.2097-2024.202405059
[12]	郭灵怡, 刘艳超, 高路, 刘瑞瑶, 吕权真, 俞媛. 醋酸卡泊芬净单硬脂酸甘油酯纳米粒抗白色念珠菌感染的增效作用研究 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202310043
[13]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[14]	王鹏, 陈顺, 赵逸, 高守红, 王志鹏. 卡培他滨致小鼠手足综合征模型的建立及评价 . 药学实践与服务, 2024, 42(9): 385-388, 398. doi: 10.12206/j.issn.2097-2024.202308045
[15]	夏哲炜, 曾垣烨, 朱海菲, 李育, 陈啸飞. 核磁共振磷谱法测定磷酸氢钙咀嚼片中药物含量 . 药学实践与服务, 2024, 42(9): 399-401, 406. doi: 10.12206/j.issn.2097-2024.202404063
[16]	陈怡君, 王卓, 何苗, 张宇, 田泾. 泌尿系统碎石术抗菌药物预防使用合理管控实践 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402034
[17]	张岩, 李炎君, 刘家荟, 邓娇, 原苑, 张敬一. 药物性肝损伤不良反应分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404034
[18]	张元林, 宋凯, 孙蕊, 舒飞, 舒丽芯, 杨樟卫. 基于真实世界数据的药物利用研究综述 . 药学实践与服务, 2024, 42(6): 238-243. doi: 10.12206/j.issn.2097-2024.202312010
[19]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
[20]	孙丹倪, 黄勇, 张嘉宝, 王培. 代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049

点击查看大图

计量

文章访问数: 3248
HTML全文浏览量: 395
PDF下载量: 627
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

1例重症患者抗感染个体化给药策略分析

doi: 10.3969/j.issn.1006-0111.2017.06.018

The individualized anti-infective treatment strategy for a critically ill patient

计量

1例重症患者抗感染个体化给药策略分析

doi: 10.3969/j.issn.1006-0111.2017.06.018

1. 复旦大学附属中山医院药剂科, 上海 200032

2. 上海交通大学医学院附属瑞金医院药剂科, 上海 200025

English Abstract

The individualized anti-infective treatment strategy for a critically ill patient

1. Department of Pharmacy, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, China

2. Department of Pharmacy, Ruijin Hospital Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China

全文HTML

目录

留言板

1例重症患者抗感染个体化给药策略分析

doi: 10.3969/j.issn.1006-0111.2017.06.018

The individualized anti-infective treatment strategy for a critically ill patient

计量

出版历程

1例重症患者抗感染个体化给药策略分析

doi: 10.3969/j.issn.1006-0111.2017.06.018

1. 复旦大学附属中山医院药剂科, 上海 200032 2. 上海交通大学医学院附属瑞金医院药剂科, 上海 200025

English Abstract

The individualized anti-infective treatment strategy for a critically ill patient

1. Department of Pharmacy, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, China 2. Department of Pharmacy, Ruijin Hospital Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China

全文HTML

目录

1. 复旦大学附属中山医院药剂科, 上海 200032

2. 上海交通大学医学院附属瑞金医院药剂科, 上海 200025

1. Department of Pharmacy, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, China

2. Department of Pharmacy, Ruijin Hospital Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China